Virophta
Brand names,
Virophta
Analogs
Virophta
Brand Names Mixture
Virophta
Chemical_Formula
C41H42N4O8
Virophta
RX_link
http://www.rxlist.com/cgi/generic2/verteporfin.htm
Virophta
fda sheet
Virophta
msds (material safety sheet)
Virophta
Synthesis Reference
No information avaliable
Virophta
Molecular Weight
718.794 g/mol
Virophta
Melting Point
No information avaliable
Virophta
H2O Solubility
No information avaliable
Virophta
State
Solid
Virophta
LogP
3.743
Virophta
Dosage Forms
Powder for solution to be mixed for injection (2mg verteporfin/mL reconstituted verteporfin)
Virophta
Indication
For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.
Virophta
Pharmacology
Verteporfin, otherwise known as benzoporphyrin derivative, is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
Virophta
Absorption
No information avaliable
Virophta
side effects and Toxicity
Overdose of drug and/or light in the treated eye may result in nonperfusion of normal retinal vessels with the possibility of severe decrease in vision that could be permanent. An overdose of drug will also result in the prolongation of the period during which the patient remains photosensitive to bright light.
Virophta
Patient Information
Virophta
Organisms Affected
Humans and other mammals